Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine

Vaccine

Volumn 30, Issue 11, 2012, Pages 1993-1998

  Reed, Carrie ^a   Meltzer, Martin I ^b   Finelli, Lyn ^a   Fiore, Anthony ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

Author keywords

Influenza vaccine

Indexed keywords

INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CROSS PROTECTION; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS B; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; VACCINE PRODUCTION;

CROSS PROTECTION; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, THEORETICAL; PUBLIC HEALTH; UNITED STATES; VACCINATION;

EID: 84857195146     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.098     Document Type: Article

References (21)

1. McCullers J.A., Saito T., Iverson A.R. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 2004, 78(December (23)):12817-12828.
2. Shaw M.W., Xu X., Li Y., Normand S., Ueki R.T., Kunimoto G.Y., et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 2002, 303(November (1)):1-8.
3. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28(February (9)):2149-2156.
4. Influenza activity-United States and worldwide, 2007-08 season. MMWR Morb Mortal Wkly Rep 2008, 57(June (25)):692-697.
5. Zhou H., Thompson W., Viboud C., Ringholz C., Abedi G., Steiner C., et al. Hospitalizations associated with influenza and respiratory syncytial virus (RSV) in the US from the 1993-94 through 2005-06 seasons. Options for the control of influenza VII 2010.
6. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010, 59(August (33)):1057-1062.
7. Chowell G., Miller M.A., Viboud C. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect 2008, 136(June (6)):852-864.
8. CDC. Seasonal influenza activity surveillance reports: 1999/00 to 2008/09 seasons. Available from: [cited May 10, 2011]. http://www.cdc.gov/flu/weekly/fluactivity.htm.
9. CDC. Influenza vaccine coverage. Available from: [cited May 10, 2011]. http://www.cdc.gov/flu/professionals/vaccination/vaccinecoverage.htm.
10. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine-Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008, 57(April (15)):393-398.
11. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199(January (2)):159-167.
12. Coleman L.A., Kieke B., Irving S., Shay D.K., Vandermause M., Lindstrom S., et al. Comparison of influenza vaccine effectiveness using different methods of case detection: clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine 2011, 29(January (3)):387-390.
13. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Izu A., Groth N., et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51(November (9)):997-1004.
14. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361(September (13)):1260-1267.
15. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355(December (24)):2513-2522.
16. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198(August (3)):312-317.
17. Skowronski D.M., De Serres G., Dickinson J., Petric M., Mak A., Fonseca K., et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009, 199(January (2)):168-179.
18. Skowronski D.M., Masaro C., Kwindt T.L., Mak A., Petric M., Li Y., et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007, 25(April (15)):2842-2851.
19. Talbot H.K., Griffin M.R., Chen Q., Zhu Y., Williams J.V., Edwards K.M. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011, 203(February (4)):500-508.
20. Wang Z., Tobler S., Roayaei J., Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009, 301(March (9)):945-953.
21. Vodeiko G.M., McInnis J., Chizhikov V., Levandowski R.A. Genetic and phenotypic analysis of reassortants of high growth and low growth strains of influenza B virus. Vaccine 2003, 21(September (25-26)):3867-3874.